Market Research Reports and Industry Reports

United States Pediatric Vaccine Market 2017 Demand, Insights, Analysis, Opportunities Segmentation and Forecast to 2024

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS

United States Pediatric Vaccine market is likely to reach nearly US$ 10 Billion by 2024.
 
 Growth in US pediatric vaccine market can be attributed to factors such as increased disease awareness, growing public acceptance, increasing government focus on immunization programs and increased government funding for the vaccine development.
 
 The research report titled “United States Pediatric Vaccine Market 2017 – Demand, Insights, Analysis, Opportunities Segmentation and Forecast to 2024” examines the market dynamics, competitive landscape and discusses major trends. The study describes an in–depth analysis of the United States pediatric vaccine market.
 
 The report contains a granular analysis of the market segmentation, reveal facts on the market size, volume and revenues and provides forecasts through 2024. The report also provides a deep and thorough evaluation of the top 10 pediatric vaccines by disease indication. On the basis of disease indication, the top 10 pediatric vaccines provide an in-depth analysis of doses administered, number of children being vaccinated and market size. The report also explores detailed description of growth drivers and inhibitors of the United States pediatric vaccine market.
 
 The report concludes with the profiles of major players in the United States pediatric vaccine market. The key market players are evaluated on various parameters such as company overview, pediatric vaccine portfolios and latest development & trends of the pediatric vaccine market.
 
 Major Pediatric Vaccines (Disease Indication) Covered Under This Report Are:
 

 Diphtheria, Tetanus & Pertussis (DTap)
 Hepatitis A
 Varicella/Chicken Pox
 Pneumococcal
 Haemophilus Influenzae Type B (HIB)
 Polio
 Rotavirus
 Hepatitis B
 Influenza Pediatric
 Measles, Mumps & Rubella (MMR)
 
 Key Companies Covered in the Report are as follows:
 

 Sanofi Pasteur
 GlaxoSmithKline(GSK)
 Merck & Co.
 Pfizer Inc
 Grifols
 
 Key Deliverables in the Study
 

 Market Definition for the specified topic along with identification of key drivers and inhibitors for the market
 It provides a growth map over time to understand the industry growth rate
 It provides a seven-year forecast assessed based on how the market is predicted to grow
 It helps in understanding the key product segments and their future
 It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
 A comprehensive list of key market players along with the analysis of their current pediatric vaccines portfolios and latest development and trends.
  

 1. Executive Summary
 
 2. Market Size & Analysis: United States Pediatric Vaccine (2010 – 2024)
 
 3. United States Pediatric Vaccine Market Share and Y–o–Y Growth (%)
 
 4. Key Market Drivers and Inhibitors of the United States Pediatric Vaccine Market
 4.1 Market Drivers
 4.2 Market Inhibitors
 
 5. United States Pediatric Vaccine Market – By Disease Indication (2010 – 2024)
 5.1 Diphtheria, Tetanus & Pertussis (DTap)
 5.1.1 Doses Administered (Volume)
 5.1.2 Number of Children Being Vaccinated (Volume)
 5.1.3 Market Size and Forecast (Value)
 5.2 Hepatitis A
 5.2.1 Doses Administered (Volume)
 5.2.2 Number of Children Being Vaccinated (Volume)
 5.2.3 Market Size and Forecast (Value)
 5.3 Varicella / Chicken Pox
 5.3.1 Doses Administered (Volume)
 5.3.2 Number of Children Being Vaccinated (Volume)
 5.3.3 Market Size and Forecast (Value)
 5.4 Pneumococcal
 5.4.1 Doses Administered (Volume)
 5.4.2 Number of Children Being Vaccinated (Volume)
 5.4.3 Market Size and Forecast (Value)
 5.5 Haemophilus Influenzae Type B (HIB)
 5.5.1 Doses Administered (Volume)
 5.5.2 Number of Children Being Vaccinated (Volume)
 5.5.3 Market Size and Forecast (Value)
 5.6 Polio
 5.6.1 Doses Administered (Volume)
 5.6.2 Number of Children Being Vaccinated (Volume)
 5.6.3 Market Size and Forecast (Value)
 5.7 Rotavirus
 5.7.1 Doses Administered (Volume)
 5.7.2 Number of Children Being Vaccinated (Volume)
 5.7.3 Market Size and Forecast (Value)
 5.8 Hepatitis B
 5.8.1 Doses Administered (Volume)
 5.8.2 Number of Children Being Vaccinated (Volume)
 5.8.3 Market Size and Forecast (Value)
 5.9 Influenza Pediatric
 5.9.1 Doses Administered (Volume)
 5.9.2 Number of Children Being Vaccinated (Volume)
 5.9.3 Market Size and Forecast (Value)
 5.10 Measles, Mumps & Rubella (MMR)
 5.10.1 Doses Administered (Volume)
 5.10.2 Number of Children Being Vaccinated (Volume)
 5.10.3 Market Size and Forecast (Value)
 
 6. Key Companies Analysis
 6.1 Sanofi Pasteur
 6.1.1 Business Overview
 6.1.2 Pediatric Vaccine Portfolios
 6.1.3 Pedaitric Vaccine – Latest Development & Trends
 6.2 GlaxoSmithKline (GSK)
 6.2.1 Business Overview
 6.2.2 Pediatric Vaccine Portfolios
 6.2.3 Pediatric Vaccine – Latest Development & Trends
 6.3 Merck & Co.
 6.3.1 Business Overview
 6.3.2 Pediatric Vaccine Portfolios
 6.3.3 Pediatric Vaccine – Latest Development & Trends
 6.4 Pfizer Inc.
 6.4.1 Business Overview
 6.4.2 Pediatric Vaccine Portfolios
 6.4.3 Pediatric Vaccine – Latest Development & Trends
 6.5 Grifols
 6.5.1 Business Overview
 6.5.2 Pediatric Vaccine Portfolios
 6.5.3 Pediatric Vaccine – Latest Development & Trends
  


List Of Tables

 Table 3–1: United States Pediatric Vaccines Market Share (Percent), 2010 – 2016
 Table 3–2: United States Pediatric Vaccine Market Share Forecast (Percent), 2017 – 2024


List Of Figures

 

Figure 2–1: United States Pediatric Vaccine Market (Million US$), 2010 – 2016
Figure 2–2: United States Pediatric Vaccines Market Forecast (Million US$), 2017 – 2024
Figure 4–19: DTap Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–20: DTap Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–21: Number of Children Being Vaccinated with DTap Vaccine (in Million),2010 – 2016
Figure 4–22: Number of Children Being Vaccinated with DTap Vaccine Forecast (in Million),2017 – 2024
Figure 4–23: DTap Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–24: DTap Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–43: Hepatitis A Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–44: Hepatitis A Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–45: Number of Children Being Vaccinated with Hepatitis A Vaccine (in Million),2010 – 2016
Figure 4–46: Number of Children Being Vaccinated with Hepatitis A Vaccine Forecast (in Million),2017 – 2024
Figure 4–47: Hepatitis A Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–48: Hepatitis A Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–49: Varicella Vaccine Doses Administered (in Million), 2010–2016
Figure 4–50: Varicella Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–51: Number of Children Being Vaccinated with Varicella Vaccine (in Million),2010 – 2016
Figure 4–52: Number of Children Being Vaccinated with Varicella Vaccine Forecast (in Million),2017 – 2024
Figure 4–53: Varicella Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–54: Varicella Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–25: Pneumococcal Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–26: Pneumococcal Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–27: Number of Children Being Vaccinated with Pneumococcal Vaccine (in Million),2010 – 2016
Figure 4–28: Number of Children Being Vaccinated with Pneumococcal Vaccine Forecast (in Million),2017 – 2024
Figure 4–29: Pneumococcal Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–30: Pneumococcal Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–7: HIB Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–8: HIB Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–9: Number of Children Being Vaccinated with HIB Vaccine (in Million),2010 – 2016
Figure 4–10: Number of Children Being Vaccinated with HIB Vaccine Forecast (in Million),2017 – 2024
Figure 4–11: HIB Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–12: HIB Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–13: Polio Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–14: Polio Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–15: Number of Children Being Vaccinated with Polio Vaccine (in Million),2010 – 2016
Figure 4–16: Number of Children Being Vaccinated with Polio Vaccine Forecast (in Million),2017 – 2024
Figure 4–17: Polio Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–18: Polio Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–31: Rotavirus Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–32: Rotavirus Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–33: Number of Children Being Vaccinated with Rotavirus Vaccine (in Million),2010 – 2016
Figure 4–34: Number of Children Being Vaccinated with Rotavirus Vaccine Forecast (in Million),2017 – 2024
Figure 4–35: Rotavirus Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–36: Rotavirus Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–37: Hepatitis B Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–38: Hepatitis B Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–39: Number of Children Being Vaccinated with Hepatitis B Vaccine (in Million),2010 – 2016
Figure 4–40: Number of Children Being Vaccinated with Hepatitis B Vaccine Forecast (in Million),2017 – 2024
Figure 4–41: Hepatitis B Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–42: Hepatitis B Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–55: Influenza Pediatric Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–56: Influenza Pediatric Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–57: Number of Children Being Vaccinated with Influenza Pediatric Vaccine (in Million),2010 – 2016
Figure 4–58: Number of Children Being Vaccinated with Influenza Pediatric Vaccine Forecast (in Million),2017 – 2024
Figure 4–59: Influenza Pediatric Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–60: Influenza Pediatric Vaccine Market Value Forecast (in Million US$), 2017 – 2024
Figure 4–1: MMR Vaccine Doses Administered (in Million), 2010 – 2016
Figure 4–2: MMR Vaccine Doses Administered Forecast (in Million), 2017 – 2024
Figure 4–3: Number of Children Being Vaccinated with MMR Vaccine (in Million),2010 – 2016
Figure 4–4: Number of Children Being Vaccinated with MMR Vaccine Forecast (in Million),2017 – 2024
Figure 4–5: MMR Vaccine Market Value (in Million US$), 2010 – 2016
Figure 4–6: MMR Vaccine Market Value Forecast (in Million US$), 2017 – 2024

Companies Mentioned

Sanofi Pasteur,
GlaxoSmithKline(GSK),
Merck & Co.,
Pfizer Inc,
Grifols
  


NG/RTE – France-Britain IFA2 Electrical Interconnection – United Kingdom - Project Profile

Synopsis NG/RTE France-Britain IFA2 Electrical Interconnection United Kingdom - Project Profile contains information on the scope of the project including project overview and location. The profile also details project

USD 75View Report

Private – Gas to Grid Biogas Plant – United Kingdom - Project Profile

Synopsis Private Gas to Grid Biogas Plant United Kingdom - Project Profile contains information on the scope of the project including project overview and location. The profile also details

USD 75View Report

United States Human Machine Interface (HMI) Market Report 2017

In this report, the United States Human Machine Interface (HMI) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end

USD 3800View Report

United States Viscosity Modifier Market Report 2017

In this report, the United States Viscosity Modifier market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

USD 3800View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 850
  • Hard Copy    USD 950
  • Site Licence    USD 1450
  • Enterprise Wide Licence    USD 1450
$ 850

Reports Details

Published Date : Oct 2017
No. of Pages :115
Country :United States of America
Category :Healthcare
Publisher :DPI Research
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube